BUZZ-RBC Capital Markets says <a href="https://laohu8.com/S/GILD">Gilead</a>'s Yeztugo sales to beat Q3 estimates; shares up** Shares of drugmaker Gilead GILD.O rise 5% to $123.58
** RBC Capital Markets estimates GILD's HIV prevention drug Yeztugo could beat consensus expectations in Q3, projecting sales of $45 million compared to the Street's $35 million, driven by switching demand and early uptake
** CVS's decision not to cover Yeztugo yet, along with formulary delays and continued use of generic Truvada, may limit near-term uptake, brokerage adds
** RBC Capital Markets expects a Q3 beat for GILD's HIV drug Biktarvy, but continues to monitor for any potential MFN impact longer term
** Company is expected to report Q3 earnings on October 30
** Including session moves, stock up 33.98% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.